Bristol Myers posts quarterly loss, revenue rises 5%
Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio and Mirati Therapeutics offset a 5% increase in revenue.
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
Is Bristol Myers Squibb A Buy At These Bottom Levels?
BMY has been upgraded to a Buy, with the stock already yielding 5.02% at the time of writing and the Seeking Alpha Quant still grading its dividend safety at B-. Combined with the promising profita...
Bristol Myers Squibb and Cellares reach $380 mln supply deal for CAR-T therapies
Bristol Myers Squibb and Cellares said on Monday they have reached a $380 million deal to supply CAR-T cell therapies to more patients.
3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations
Bristol Myers has an uncertain future, but with a strong track record and impressive cash flow it's still a top healthcare stock to own. Verizon Communications offers investors a mouth-watering yie...
3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500
The U.S. stock market continues to climb the wall of worry, despite persistent inflation and heightened geopolitical risks. The S&P 500 has returned 26% in the past 12 months, while the Wilshire 50...
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
Bristol Myers Squibb is turning on its innovative machine to get through recent patent cliffs. Novartis recently became a thinner company that is laser-focused on developing new medicines.
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.
6 Ultimate Dividend Stocks for Long-Term Passive Income Growth
Sponsored: Find a Qualified Financial Advisor Finding a qualified financial advisor doesn't have to be hard.
Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
Bristol Myers Squibb's share price continues to move sideways despite several regulatory approvals for its innovative drugs in the past six months. On April 2, 2024, the EMA approved Reblozyl as a ...
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in v...
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
In the latest trading session, Bristol Myers Squibb (BMY) closed at $51.60, marking a +0.98% move from the previous day.
Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival
J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai's approach to AI.
Bristol Myers (BMY) Reports Positive Colorectal Cancer Study Data
Bristol Myers' (BMY) Krazati, in combination with cetuximab, demonstrates clinically meaningful activity as a targeted treatment option for patients with previously treated KRASG12C-mutated locally...
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma
Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
Related Companies